Sonida Senior Living reported a strong Q2 performance following its $1.8 billion acquisition of CNL, with revenue rising 122% year-over-year. The integration of new communities has driven significant growth in net operating income (NOI) and improved occupancy rates, supporting management's strategy for operational improvements. Despite elevated leverage at $1.6 billion and risks from interest rate exposure, refinancing efforts have extended debt maturities and enhanced financial flexibility. The company’s current valuation appears to undervalue its growth potential, leading to a maintained Buy rating despite execution and interest rate risks.
Sonida Senior Living's recent growth phase is notable amid a mixed Real Estate sector performance. For readers following Real Estate, here is Pluang's market snapshot as of Sep 14, 2026 19:14 WIB: 11 of 22 US Real Estate stocks rose today. Opendoor Technologies Inc closed at USD 2.72, down 2.51%, while Prologis Inc and Crown Castle International Corp ended at USD 134.07 and USD 75.00, down 1.22% and 0.82% respectively.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
